Report

Global life science analytics market is projected to witness a CAGR of 8.12% during the forecast period 2024-2031F, growing from USD 17.66 billion in 2023 to USD 32.98 billion in 2031F. The life science analytics market is a rapidly growing market due to factors such as increasing prevalence of chronic diseases such as cardiovascular diseases, diabetes and cancer, increasing application of artificial intelligence and machine learning in life sciences and rising adoption of advanced analytics solutions in pharmaceuticals and clinical trials.
Any analytical tool used by pharmaceutical companies, clinical research organizations, and a host of other departments, such as supply chain, marketing, pharmacovigilance, and research, may be categorized as a life science analytics tool. It is a clinical data analysis technique that offers forecasting tools for better patient treatment and management. Real-world statistical data analysis skills have become critical in an ever-evolving environment that seeks innovation. Life science businesses are increasingly using data analytics to sort through social media data, CRO, and EHR data in order to better guide their product choices, enhance their current offerings, and improve patient outcomes. Through the use of platforms like Qlik, businesses may investigate large amounts of data and obtain market insights that can be used to R&D, clinical, GMA, and commercial operations. According to a recent Deloitte poll, 91% of life sciences businesses intend to invest in R&D innovation in 2023, and over half of them are optimistic about the industry's prospects for that year. However, the success of the present high-risk, high-cost R&D framework still has to overcome major financial challenges. To overcome these obstacles and prosper in the post-pandemic environment, life sciences research and development (R&D) companies need to give top priority to accelerating digital transformation projects, strategic changes, and commercial restructuring.
Increasing Application of Artificial Intelligence and Machine Learning in Life Sciences
Most organizations in life sciences and healthcare have only scratched the surface of AI and ML's potential. AI and ML are primarily being used to automate repetitive tasks and standard business processes. However, AI is now widely recognized as a strategic business issue in this area and is actively being discussed at the board and C-suite levels. By combining AI technology with the fields of medicine and science, organizations are looking for opportunities to transform some of their most critical processes and achieve sustainable competitive advantage through AI. AI is predicted to have a revolutionary effect on biopharma research and development (R&D) within the next three to five years, especially in the area of drug discovery. Life sciences businesses will follow proof-of-concept and pilot programs for AI in many other areas of the value chain in the interim.
As per a report published by Philips's Future Health Index report for 2024, 2,800 respondents from 14 different countries indicated that 85% of them invest in technology or plan to do so in the next three years.
Rising Adoption of Advanced Analytics Solutions in Pharmaceuticals, Medical Devices and Clinical Trials
Healthcare leaders see a wide range of opportunities to improve patient care by bringing data from disparate sources together in a meaningful way. Healthcare professionals believe data-driven insights could help optimize treatment plans and care pathways, identify evidence-based practices, and reduce waiting lists for diagnostic and elective procedures. However, to deliver on these possibilities, healthcare leaders recognize they first need to get the foundations right. The foundation of seamless data integration can be done by improving the accuracy of patient data, enhancing interoperability among different platforms and healthcare settings, and strengthening data security and privacy. Healthcare executives see several chances to enhance patient care by integrating data from various sources. Healthcare practitioners think data-driven insights might assist in finding evidence-based treatments, streamline treatment plans and care pathways, and shorten waiting lists for elective and diagnostic procedures. Healthcare executives understand that, in order to realize these opportunities fully, they must first lay the necessary groundwork. Improving patient data accuracy, boosting platform and healthcare setting interoperability, and fortifying data security and privacy are the cornerstones of a smooth data integration process.
In 2024, Yotta Data Services announced a partnership with Partex NV to improve healthcare services in drug discovery and patient care. The partnership will leverage Yotta's Shakti-Cloud platform, backed by Nvidia H100 GPU processing infrastructure, to enable Partex's AI-driven healthcare solutions. The collaboration intends to create AI-based solutions that will improve healthcare services' efficacy and efficiency, especially in the areas of patient care and drug development.
Predictive Analytics is Expected to Register Fast Growth in the Forecast Period
Predictive analytics may improve healthcare by assisting in clinical decision-making, providing direction for population health management, and promoting value-based treatment. In the healthcare industry, predictive analytics is essential in enhancing patient outcomes and the delivery of treatment. This kind of analytics enables health organizations to predict future outcomes from an operational and clinical standpoint by utilizing past data. Healthcare organizations seeking value-based care may find this capacity especially helpful, as it can assist stakeholders in identifying areas where their present strategies may be insufficient and working toward changing them.
For instance, mPulse Mobile, Inc reported strong Q1 2024 growth and launched a new predictive analytics and engagement solution in 2024. In addition, mPulse announced the opening of a new category in the digital health ecosystem with the introduction of its omnichannel engagement and integrated predictive analytics product capabilities. Growth at mPulse was driven by increased automation and efficiency in its business areas for health portals, predictive analytics, and omnichannel interaction.
North America Dominates the Global Life Science Analytics Market
In the life sciences analytics sector, North America serves as the epicenter for innovation and technical developments. Numerous well-known biotechnology, pharmaceutical, and medical device companies are based in the area, and they extensively engage in data analytics to maintain regulatory compliance, boost sales and marketing initiatives, improve clinical trial quality, and increase productivity in research and development. Leading research institutes and a strong healthcare system are two other factors that make North America a leader in life science analytics. Adoption of advanced analytics solutions is also required in North American countries due to their complex regulatory framework and well-established data management processes.
In 2024, OpenAI Inc. announced its partnership with Color Health, Inc. to apply its AI models to cancer detection and treatment, hence expanding the application of AI in healthcare. Using OpenAI's GPT-4o model, Color Health, a startup that was established in 2013 as a genetic testing firm, developed an AI assistant or "copilot" in 2024. The copilot assists physicians in developing pretreatment programs for patients with cancer diagnoses as well as strategies for cancer screening.
Future Market Scenario (2024-2031F)
The value of data analytics in fostering innovation and growth is now well-acknowledged in the life science sector. With applications ranging from predictive modeling to personalized medicine, this technology has the potential to completely change the way the world sees healthcare. Artificial intelligence is developing at a fast pace; it transforms the commercial world and increases our trust in utilizing automation, robots, and machine learning. Unlike traditional approaches, modern machine learning and artificial intelligence systems can handle vast data sets. It improves the ability to foresee and manage, which, in the end, means saving lives in the healthcare industry. Data analytics appears to have a bright and exciting future in the life science sector. Given the industry's ongoing adoption of AI technology and data-driven methodologies, it is essential to discuss the ethical implications and issues associated with these developments. In order to improve patient outcomes, streamline operations, and spur innovation, the life science industry can responsibly and effectively harness the power of data analytics by investing in data privacy and security, addressing biases, fostering transparency, encouraging collaboration, and developing a skilled workforce.
Key Players Landscape and Outlook
Several medical device companies like Oracle Systems Corporation, IBM Corporation, Accenture Plc, IQVIA Holdings Inc, Cognizant Technology Solutions Corporation, Wipro Enterprises Limited, Allscripts Healthcare Solutions Inc, Optum Inc, Microsoft Corporation and SAS Institute Inc are flourishing in the global life science analytics market by planning and adopting new strategies. They are complying with new strategic initiatives for AI and ML technologies to increase their market presence. New agreements, contracts, acquisitions, mergers, investments, and partnerships are major ways through which they are trying to achieve higher market share.
In June 2024, Simplify Healthcare Technology acquired Virtical.ai in order to expedite the integration of artificial intelligence. The consumer bases of both organizations are going to benefit greatly from the acquisition. The advanced AI platform from Virtical.ai and the well-established cloud-based platform from Simplify Healthcare, Simplify Health Cloud, will combine to deliver an effective tool that will enable payers to achieve new heights of creativity, efficiency, and growth enablers.